SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
128.80    4.60 (3.70%)
Bid:
128.20
Ask:
129.60
Spread: 1.40 (1.092%)
Market Cap: £536.34m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Pre-Close Trading Statement

30 Jul 2019 07:00

RNS Number : 1051H
James Halstead PLC
30 July 2019
 

 

 

 

30 July 2019

 

Pre-Close Trading Statement

 

 

James Halstead plc, the commercial flooring manufacturer and distributor, is providing the following trading update ahead of its final results for the year ended 30 June 2019.

 

We are pleased to report that sales for the year were ahead of the comparative year and at a record level. This, we feel, represents a creditable performance in still difficult trading conditions. Flooring installations through the year were wide ranging such as Harrow School, Euro Disney's Hotel New York and Chanel concessions across the globe and the Al Thumama Stadium in Qatar. Our healthcare business continues to make good progress and projects completed included Poissy Hospital in France and the newly built Quillota Hospital in Chile. It is particularly pleasing to report that our UK turnover (representing about 35% of total sales) is ahead of the prior year, by some 7%, in a market that seems to be quite robust despite the well reported high street retailer issues.

 

Across many regions, but especially in Europe competition is ever increasing with new entrants peddling an increasing array of flooring of various degrees of quality and availability. In the German market we have maintained market share but turnover was at a lower level. There are markets with double digit growth and France, South America and Holland are examples. We remain confident that our investment in marketing, sampling, sales representation and training / technical support continue to differentiate us from the pack.

 

Raw material prices are stable and the availability problems of last year have ameliorated and working capital remains robustly managed with our cash generation secure. Our long term focus on delivery of shareholder returns is undiminished.

 

Our profit for the year has grown and will be at a record level, representing modest growth.

 

 

 

 

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

 

 

Enquiries:

 

James Halstead plc

Telephone: 0161 767 2500

Mark Halstead, Chief Executive

Gordon Oliver, Finance Director

Hudson Sandler

Telephone: 020 7796 4133

Nick Lyon

Nick Moore

Panmure Gordon (Nominated advisor and broker)

Telephone: 020 7886 2500

Ben Thorne

Dominic Morley

Arden Partners (Broker)

Telephone: 020 7614 5900

Tom Price

Matthew Groves

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTDKLFLKDFFBBE
Date   Source Headline
25th Jan 20107:00 amRNSPre-close Trading Statement
4th Jan 20107:00 amRNSBlocklisting Interim Review
31st Dec 20097:00 amRNSTotal Voting Rights
18th Dec 20094:00 pmRNSAnnual Report and Accounts
14th Dec 200911:30 amRNSDirector's shareholding
10th Dec 20093:00 pmRNSDirector's shareholding
7th Dec 20091:50 pmRNSDirector's shareholding
4th Dec 20091:00 pmRNSDividend Declaration
4th Dec 20097:00 amRNSAGM Statement
12th Oct 200912:00 pmRNSDirector/PDMR Shareholding
29th Sep 20097:00 amRNSPreliminary Results
17th Sep 200911:37 amRNSNotice of Preliminary Results
29th Jul 20097:00 amRNSPre-Close Trading Update
1st Jul 200912:30 pmRNSBlocklisting Interim Review
30th Mar 20094:45 pmRNSDividend Declaration - Correction
30th Mar 20097:00 amRNSInterim Results
17th Mar 20093:12 pmRNSNotice of Results
26th Feb 20098:00 amRNSBlocklisting Interim Review
28th Jan 20097:00 amRNSPre-close Trading Statement
22nd Dec 200812:30 pmRNSAnnual Report and Accounts
10th Dec 20087:00 amRNSAGM Statement
8th Oct 200812:00 pmRNSDirector/PDMR Shareholding
6th Oct 20085:00 pmRNSDirector/PDMR Shareholding
30th Sep 20085:08 pmRNSDirectors' Dealings
30th Sep 20087:00 amRNSFinal Results
24th Sep 20087:00 amRNSExecutive Board Appointment
19th Sep 20084:50 pmRNSSecond Price Monitoring Extn
19th Sep 20084:35 pmRNSPrice Monitoring Extension
16th Sep 200810:00 amRNSNotice of Results
4th Sep 20087:00 amRNSNotice of Results
31st Jul 20087:00 amRNSTotal Voting Rights
3rd Jul 20081:00 pmRNSBlocklisting Interim Review
1st Jul 20087:00 amRNSTrading Statement
11th Jun 20081:00 pmRNSAdditional Listing
30th May 200810:58 amRNSTotal Voting Rights
14th May 20087:00 amRNSDirector/PDMR Shareholding
31st Mar 20087:00 amRNSInterim Results
1st Feb 20084:50 pmRNSTotal Voting Rights
31st Jan 20083:49 pmRNSAdditional Listing
30th Jan 20082:16 pmRNSDirector/PDMR Shareholding
28th Jan 20087:00 amRNSPre-close Trading Update
23rd Jan 20084:31 pmRNSBlock Listing Returns
15th Jan 20081:11 pmRNSDirector/PDMR Shareholding
7th Jan 200812:43 pmRNSDirector/PDMR Shareholding
7th Dec 20077:01 amRNSAGM Statement
15th Nov 200710:56 amRNSAnnual Report and Accounts
1st Oct 20077:01 amRNSFinal Results
10th Sep 20079:38 amRNSNotice of Results
31st Aug 20073:33 pmRNSTotal Voting Rights
23rd Aug 20071:21 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.